Timothy Lu is CEO and Co-Founder of Senti Biosciences, a biotechnology company applying synthetic biology to create next-generation cell and gene therapies. Tim graduated with his SB and MEng from MIT, and his MD/PhD from the Harvard-MIT Health Sciences and Technology program. Tim joined the MIT faculty in 2010 leading the Synthetic Biology Group in the Department of Electrical Engineering and Computer Science and the Department of Biological Engineering at MIT. He is a core member of the MIT Synthetic Biology Center and a co-founder of multiple biotechnology companies innovating new diagnostic and therapeutic technologies for human health, including Senti Biosciences, Synlogic, Eligo Biosciences, BiomX, Tango Therapeutics, Corvium, and Engine Biosciences.
Tim’s research focuses on engineering computing and memory into living cells and applying these technologies to create adaptive cell and gene therapies for important human diseases. His work also includes developing novel technology platforms to interrogate and correct diseased cell states. He is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award, the 2018 Xconomy Scientific Founder of the Year, among others.